NASDAQ:NAMSW NewAmsterdam Pharma (NAMSW) Stock Price, News & Analysis $16.51 0.00 (0.00%) As of 08/26/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsNews and TrendsOwnershipSEC Filings About NewAmsterdam Pharma Stock (NASDAQ:NAMSW) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get NewAmsterdam Pharma alerts:Sign Up Key Stats Today's Range$16.51▼$16.5150-Day Range$14.49▼$25.1052-Week Range$12.67▼$30.45VolumeN/AAverage Volume2,142 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview NewAmsterdam Pharma, Inc. is a clinical-stage biotechnology company focused on the development of orally delivered peptide therapeutics for the treatment of metabolic diseases. Drawing upon proprietary peptide chemistry and formulation technologies, the company aims to transform injectable treatments for conditions such as type 2 diabetes, obesity and related cardiometabolic disorders into convenient, once-daily oral medications. By harnessing advances in peptide stabilization and targeted delivery, NewAmsterdam Pharma seeks to improve patient adherence and expand access to novel therapies. The company’s lead program is an oral glucagon‐like peptide‐1 (GLP-1) receptor agonist currently in early clinical trials. This candidate is designed to mimic the metabolic benefits of existing GLP-1 injectables— including glucose control and weight reduction—while offering the ease of an oral tablet. In addition, NewAmsterdam Pharma is advancing a pipeline of next-generation oral candidates, including dual agonists that target GLP-1 and other receptors implicated in energy homeostasis. These programs leverage the same foundational chemistry platform to address a broad spectrum of metabolic and inflammatory indications. Founded in 2020 and headquartered in New York City, NewAmsterdam Pharma has assembled a leadership team with deep expertise in peptide drug development, pharmaceutical formulation and clinical research. The company is supported by a consortium of life science investors and collaborates with academic and industry partners to advance its oral peptide platform. While still in the early phases of clinical evaluation, NewAmsterdam Pharma is positioned to redefine treatment paradigms for chronic metabolic diseases through its innovation in oral peptide therapeutics.AI Generated. May Contain Errors. Read More Receive NAMSW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NewAmsterdam Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NAMSW Stock News HeadlinesNewAmsterdam Pharma Appoints New Principal Accounting OfficerAugust 14, 2026 | tipranks.comNewAmsterdam Pharma reports $3.7 million second quarter revenueAugust 5, 2026 | quiverquant.comQSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.August 27 at 1:00 AM | Altimetry (Ad)NewAmsterdam Pharma: Obicetrapib Is More Than Another LDL-Lowering PillJuly 25, 2026 | seekingalpha.comNewAmsterdam Pharma: Advancing EU Launch and CV Outcomes Pathway Underpins Unchanged $48 Price Target and Buy RatingJuly 24, 2026 | tipranks.comNewAmsterdam Pharma Wins EMA Backing for Obicetrapib TherapiesJuly 24, 2026 | tipranks.comTop Executive Makes Major Move With NewAmsterdam Pharma SharesJuly 22, 2026 | tipranks.comNewAmsterdam Pharma Announces COO Transition and Advisory RoleJuly 22, 2026 | tipranks.comSee More Headlines NAMSW Stock Analysis - Frequently Asked Questions How have NAMSW shares performed this year? NewAmsterdam Pharma's stock was trading at $22.99 at the beginning of the year. Since then, NAMSW shares have decreased by 29.1% and is now trading at $16.30. Who are NewAmsterdam Pharma's major shareholders? NewAmsterdam Pharma's top institutional investors include Headlands Technologies LLC. How do I buy shares of NewAmsterdam Pharma? Shares of NAMSW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today8/27/2026Next Earnings (Estimated)11/11/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (16m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 NAMSW's financial health is in the Green zone, according to TradeSmith. NAMSW has been in this zone for over 16 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:NAMSW CIK1936258 Webwww.newamsterdampharma.com Phone31 35 206 2971FaxN/AEmployees29Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$7.12 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:NAMSW) was last updated on 8/27/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
